TWI262919B - Naphthyridine derivative - Google Patents
Naphthyridine derivative Download PDFInfo
- Publication number
- TWI262919B TWI262919B TW089122260A TW89122260A TWI262919B TW I262919 B TWI262919 B TW I262919B TW 089122260 A TW089122260 A TW 089122260A TW 89122260 A TW89122260 A TW 89122260A TW I262919 B TWI262919 B TW I262919B
- Authority
- TW
- Taiwan
- Prior art keywords
- ethyl
- methyl
- group
- chlorophenyl
- compound
- Prior art date
Links
- 150000005054 naphthyridines Chemical class 0.000 title claims description 10
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- -1 3-(4-cyclohexyl-1-ethyl-7-methyl —2 —carbonyl-1,2-dihydro-1,8-naphthyridin-3-yl)propionic acid Chemical compound 0.000 claims description 15
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 12
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 10
- 230000002079 cooperative effect Effects 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 235000019260 propionic acid Nutrition 0.000 claims description 5
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 5
- 150000003536 tetrazoles Chemical class 0.000 claims description 3
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 claims 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical group N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 claims 1
- UVBBXHDRJXIQCH-UHFFFAOYSA-N 7-methyl-1h-1,8-naphthyridin-2-one Chemical compound C1=CC(=O)NC2=NC(C)=CC=C21 UVBBXHDRJXIQCH-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- KIPPZKZTINZTIR-UHFFFAOYSA-N piperidine-1,2,2,3-tetracarboxylic acid Chemical compound N1(C(C(CCC1)C(=O)O)(C(=O)O)C(=O)O)C(=O)O KIPPZKZTINZTIR-UHFFFAOYSA-N 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 12
- 229940079593 drug Drugs 0.000 abstract description 9
- 125000001424 substituent group Chemical group 0.000 abstract description 9
- 230000003449 preventive effect Effects 0.000 abstract description 3
- 208000023504 respiratory system disease Diseases 0.000 abstract description 3
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- ZFRUGZMCGCYBRC-UHFFFAOYSA-N 1h-1,8-naphthyridin-2-one Chemical class C1=CC=NC2=NC(O)=CC=C21 ZFRUGZMCGCYBRC-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 70
- 238000006243 chemical reaction Methods 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 41
- 239000000243 solution Substances 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 238000000034 method Methods 0.000 description 30
- 239000002904 solvent Substances 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 238000012360 testing method Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- 125000000217 alkyl group Chemical group 0.000 description 9
- 238000001816 cooling Methods 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 7
- 208000006673 asthma Diseases 0.000 description 7
- 125000000623 heterocyclic group Chemical group 0.000 description 7
- 238000007639 printing Methods 0.000 description 7
- 125000006239 protecting group Chemical group 0.000 description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000012044 organic layer Substances 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 5
- 235000011054 acetic acid Nutrition 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 101150117004 atg18 gene Proteins 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229910052740 iodine Inorganic materials 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 4
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 150000002170 ethers Chemical class 0.000 description 4
- 125000000524 functional group Chemical group 0.000 description 4
- 150000008282 halocarbons Chemical group 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000001853 liver microsome Anatomy 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 150000003863 ammonium salts Chemical class 0.000 description 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 229910052751 metal Chemical class 0.000 description 3
- 239000002184 metal Chemical class 0.000 description 3
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 238000007670 refining Methods 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical class NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical class CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical class CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical class NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000008065 acid anhydrides Chemical class 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical class [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 2
- 239000004062 cytokinin Substances 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical class [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000003437 trachea Anatomy 0.000 description 2
- 230000017105 transposition Effects 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- QDLFVXRWLQSBTF-UHFFFAOYSA-N 1,1,2-triethylhydrazine Chemical compound CCNN(CC)CC QDLFVXRWLQSBTF-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- ARDGQYVTLGUJII-UHFFFAOYSA-N 2,2-dimethylpropanimidamide;hydrochloride Chemical compound Cl.CC(C)(C)C(N)=N ARDGQYVTLGUJII-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- MUBLRPCYTXJFFO-UHFFFAOYSA-N 2-methylpropanenitrile hydrochloride Chemical compound Cl.CC(C#N)C MUBLRPCYTXJFFO-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- YHUJJTKAGZRTPA-UHFFFAOYSA-N 3-(4-cyclohexyl-1-ethyl-7-methyl-2-oxo-1,8-naphthyridin-3-yl)propanenitrile Chemical compound N#CCCC=1C(=O)N(CC)C2=NC(C)=CC=C2C=1C1CCCCC1 YHUJJTKAGZRTPA-UHFFFAOYSA-N 0.000 description 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- RDSNSVRMCQTDQZ-UHFFFAOYSA-N 4-(methylsulfonyloxymethyl)benzenesulfonic acid Chemical compound C1(=CC=C(C=C1)COS(=O)(=O)C)S(=O)(=O)O RDSNSVRMCQTDQZ-UHFFFAOYSA-N 0.000 description 1
- NXNSWCKSWXENCL-UHFFFAOYSA-N 4-chloro-5-ethoxy-5-oxopentanoic acid Chemical compound CCOC(=O)C(Cl)CCC(O)=O NXNSWCKSWXENCL-UHFFFAOYSA-N 0.000 description 1
- YXBVMSQDRLXPQV-UHFFFAOYSA-N 4-cyanobutanoic acid Chemical compound OC(=O)CCCC#N YXBVMSQDRLXPQV-UHFFFAOYSA-N 0.000 description 1
- PBNLDFDWDJGXBT-UHFFFAOYSA-N 5-ethoxy-5-oxopentanoic acid hydrochloride Chemical compound Cl.CCOC(=O)CCCC(O)=O PBNLDFDWDJGXBT-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- JJSRSMQEHCBYBR-UHFFFAOYSA-L C(C=1C(C(=O)[O-])=CC=CC1)(=O)OC.[Mg+2].COC(C=1C(C(=O)[O-])=CC=CC1)=O Chemical compound C(C=1C(C(=O)[O-])=CC=CC1)(=O)OC.[Mg+2].COC(C=1C(C(=O)[O-])=CC=CC1)=O JJSRSMQEHCBYBR-UHFFFAOYSA-L 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- XHXUANMFYXWVNG-UHFFFAOYSA-N D-menthyl acetate Natural products CC(C)C1CCC(C)CC1OC(C)=O XHXUANMFYXWVNG-UHFFFAOYSA-N 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000740205 Homo sapiens Sal-like protein 1 Proteins 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical class NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical class NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004472 Lysine Chemical class 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Chemical class NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 229910003251 Na K Inorganic materials 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Chemical class NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Chemical class OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- KJTLSVCANCCWHF-UHFFFAOYSA-N Ruthenium Chemical compound [Ru] KJTLSVCANCCWHF-UHFFFAOYSA-N 0.000 description 1
- 102100037204 Sal-like protein 1 Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- JVVXZOOGOGPDRZ-SLFFLAALSA-N [(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthren-1-yl]methanamine Chemical compound NC[C@]1(C)CCC[C@]2(C)C3=CC=C(C(C)C)C=C3CC[C@H]21 JVVXZOOGOGPDRZ-SLFFLAALSA-N 0.000 description 1
- ZXPSRPAUXQIYID-UHFFFAOYSA-N [N].[Na] Chemical compound [N].[Na] ZXPSRPAUXQIYID-UHFFFAOYSA-N 0.000 description 1
- SLEGPTUZZMEOPB-UHFFFAOYSA-N [Na].C(CCCCCCCCC)N Chemical compound [Na].C(CCCCCCCCC)N SLEGPTUZZMEOPB-UHFFFAOYSA-N 0.000 description 1
- VBTPRWXFCXZKPQ-UHFFFAOYSA-N [O].NN Chemical compound [O].NN VBTPRWXFCXZKPQ-UHFFFAOYSA-N 0.000 description 1
- WJGAPUXHSQQWQF-UHFFFAOYSA-N acetic acid;hydrochloride Chemical compound Cl.CC(O)=O WJGAPUXHSQQWQF-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 150000005305 alkyl chloride derivatives Chemical class 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 201000005008 bacterial sepsis Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- HTRXGEPDTFSKLI-UHFFFAOYSA-N butanoic acid;ethyl acetate Chemical compound CCCC(O)=O.CCOC(C)=O HTRXGEPDTFSKLI-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- BULLHNJGPPOUOX-UHFFFAOYSA-N chloroacetone Chemical compound CC(=O)CCl BULLHNJGPPOUOX-UHFFFAOYSA-N 0.000 description 1
- UXTMROKLAAOEQO-UHFFFAOYSA-N chloroform;ethanol Chemical compound CCO.ClC(Cl)Cl UXTMROKLAAOEQO-UHFFFAOYSA-N 0.000 description 1
- AGSFIZDITVHDFK-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.OC.ClC(Cl)Cl AGSFIZDITVHDFK-UHFFFAOYSA-N 0.000 description 1
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000021735 chronic enteritis Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 125000006612 decyloxy group Chemical group 0.000 description 1
- 238000000586 desensitisation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- DXPIZCZNFUTPEI-UHFFFAOYSA-O diphenylphosphanium;azide Chemical compound [N-]=[N+]=[N-].C=1C=CC=CC=1[PH2+]C1=CC=CC=C1 DXPIZCZNFUTPEI-UHFFFAOYSA-O 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- RPEUEJTZHRHZQD-UHFFFAOYSA-N ethyl 2-pyridin-3-ylpropanoate Chemical compound CCOC(=O)C(C)C1=CC=CN=C1 RPEUEJTZHRHZQD-UHFFFAOYSA-N 0.000 description 1
- WDCDAAMJNUHOIY-UHFFFAOYSA-N ethyl acetate;2-propan-2-yloxypropane Chemical compound CCOC(C)=O.CC(C)OC(C)C WDCDAAMJNUHOIY-UHFFFAOYSA-N 0.000 description 1
- RUJPPJYDHHAEEK-UHFFFAOYSA-N ethyl piperidine-4-carboxylate Chemical compound CCOC(=O)C1CCNCC1 RUJPPJYDHHAEEK-UHFFFAOYSA-N 0.000 description 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 150000002214 flavonoid derivatives Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
- DDCYYCUMAFYDDU-UHFFFAOYSA-N methyl thiohypochlorite Chemical compound CSCl DDCYYCUMAFYDDU-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- OXKUGIFNIUUKAW-UHFFFAOYSA-N n,n-dimethylformamide;hydrazine Chemical compound NN.CN(C)C=O OXKUGIFNIUUKAW-UHFFFAOYSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N naphthalene-acid Natural products C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- 229940100656 nasal solution Drugs 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- ZUPDNLCLXSWMAE-UHFFFAOYSA-N potassium;butan-2-olate Chemical compound [K+].CCC(C)[O-] ZUPDNLCLXSWMAE-UHFFFAOYSA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000009822 protein phosphorylation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 229910052707 ruthenium Inorganic materials 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- KKCBUQHMOMHUOY-UHFFFAOYSA-N sodium oxide Chemical class [O-2].[Na+].[Na+] KKCBUQHMOMHUOY-UHFFFAOYSA-N 0.000 description 1
- 229910001948 sodium oxide Inorganic materials 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- XDLNRRRJZOJTRW-UHFFFAOYSA-N thiohypochlorous acid Chemical compound ClS XDLNRRRJZOJTRW-UHFFFAOYSA-N 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000009284 tracheal contraction Effects 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
1262919 經濟部智慧財產局員工消費合作社印製 A7 B7___ 五、發明說明(1 ) 本發明係有關可有效做爲醫藥’特別是1 V型磷酸二 酯酶阻礙劑之萘啶衍生物。 先行技術中,氣喘係藉由氣管收縮重覆喘鳴與發作之 呼吸道疾病者。其病患數至今不斷增加’可預見的’今後 將更爲增加。 目前氣喘之治療中,做爲支氣管擴張劑者以胺基非林 ,茶鹼等黃嘌吟衍生物及普魯與茶酚等之/3刺激藥爲主要 使用者。 此等化合物之作用機序係於氣管平滑肌中使細胞內腺 苷3 / ,5 / —循環磷酸(c A Μ P )產生酵素之腺苷酸 循環酶進行活性化後,或藉由阻礙C A Μ Ρ分解酵素之磷 酸二酯酶(P D Ε )後,提昇細胞內之c A Μ Ρ濃度,舒 緩氣管平滑肌之收縮者。(內科6 9,2 0 7 - 2 1 4 ( 19 9 2)° 公知者,細胞內c A Μ Ρ濃度之上昇係於氣管平滑肌 引起收縮抑制(Clin,Exp.Allergy,22,337-344(1992),Drugs of the future,1 7,799-807( 1 992)),可有效改善氣喘症狀者 ο 惟,公知者發現黃嘌呤衍生物出現血壓下降,強心作 用等全身性副作用(J.Cyclic Nucleotide and Protein phosphorylation Res.,10,55 1-564(1985),J.Pharmacol.Exp.Ther ,25 7,74 1 -747( 1 99 1 )),且,/3 —刺激等易造成減敏,使用 量增加則出現手指顫抖,悸動等副作用。 另外,P D E至少分爲I〜V型之5種不同型態者, 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) — I.---^-------·裝 ---L.--訂---------^91 (請先閱讀背面之注意事項再填寫本頁) 1262919 A7 B7 經濟部智慧財產局員工消費合作社印製 五、發明說明(2 ) 分別不同分佈或機能被解開(pharmacol.Ther·,51,13-33(1991 ))。特別是I V型之P D E即使核苷酸中仍未作用於鳥苷 3 / ,5 / -循環磷酸(c G Μ P ),可特異的分解 c A Μ Ρ,確定存在於氣管平滑肌及浸潤細胞兩者中。 又,I V型P D Ε阻礙劑對於實驗鼠中藉由抗原及血 小板活化因子之嗜酸球浸潤顯示抑制作用(Eui·.〗.Pharmacol .,255,25 3-256( 1 994)),報告指出由嗜酸球之障礙性蛋白( Μ B P,E C P )之遊離被抑制之(BrJ.Pharmacol·,1 15, 39-47( 1 995))。更藉由收縮物質(組織胺,乙醯甲基膽鹼 ,L T D 4 )顯示對於氣管平滑肌之收縮具抑制作用(Br.J. Pharmacol·, 1 1 3,1 423- 1 43 1 ( 1 994)),報告指出對於氣喘息息相 關之細胞分裂素I L — 4之產生受阻(J.Invest Dermatol., 1 00,68 1 -684( 1 993)),氣管中血管滲透性之元進具有抑制作 用者(Fundam.Clin.pharmacol.,6,247-249(1992)),對於氣管 過敏症具有抑制作用(Eur 丄 Pharmacol.275,75-82(1995)), 被揭示。因此,I V型P D E阻礙劑被期待爲副作用少之 氣喘治療劑者。 做爲具有阻礙I V型P D E活性之化合物者其公知者 有含萘啶衍生物之多種化合物者。本申請人首先揭示如下 式所示於4位具環狀取代基,3位爲無取代或具有低級垸 基之萘啶衍生物者(WO 96/06843號)。 (請先閱讀背面之注意事項再填寫本頁) 裝 • I— n— ϋ It .1 ϋ tr---------. 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公t ) A7 1262919 五、發明說明(4 )
R3-^V^x-R6 ⑴ R4 R5 (式中之記號如下所示。 R 1 :低級烷基, R 2 : Η或低級烷基, r 3,R 4 : Η。 R 5 :係選自R 1 ^之基被取代亦可之環烷基,或爲選自 R 1 13之基被取代亦可之苯基, X :結合或低級亞烷基, R 6 :係選自R 1 ^之基被取代亦可之雜環基,或 — C〇2H,一 C〇〇一低級烷基,一C0NH2, 一〇H,一 NH2,一CN,一 C (NH)NH2 或 一 NHC(NH)NH2, R 1 0 · 一*鹵素,一^低級院基,一 C〇2H,或 一 C 0 2 -低級烷基。以下相同。) 又,本發明係提供以含有萘啶衍生物及其鹽者爲其特 徵之醫藥者,特別是,I V型P D E阻礙劑者。 以下,進行本發明之詳細說明。 本明細書中,所謂「低級」係指碳數1〜6個直鏈狀 或分枝之烴基鏈者。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 11.—^裝 ^—訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1262919 A7 B7__ 五、發明說明(5 ) (請先閱讀背面之注意事項再填寫本頁) 做爲「低級烷基」者以碳數爲1〜3之烷基者宜,特 別以甲基及乙基爲更理想者。做爲「低級亞烷基」者以碳 數1〜4個之亞烷基者宜,特別以亞甲基,乙烯及丙烯爲 更佳。「環烷基」係指碳數3〜8個之環烷基者宜,特別 以環己基爲更佳。「雜環基」代表具有選自氮原子,氧原 子’及硫黃原子所成群中1〜4個異項原子之單環〜三環 式雜環基者,形成交聯環者亦可,苯環與縮環亦可。理想 之該雜環爲5〜7員飽和或不飽和單環雜環基者,理想例 爲吡啶,哌啶,嗎啉,噻吩,噻唑,咪唑,四唑,吡嗪, 哌嗪者宜,更佳者爲吡啶,哌啶,四唑。 「鹵素」代表氟,氯,溴及碘者。 「被取代亦可者」代表「無取代」或「具有1〜5個 相同或相異之取代基者」。 「被取代亦可之環烷基」,「被取代亦可之雜環」及 「被取代亦可之苯基」中取代基只要可做爲此等環之取代 基使用者即可,無特別限定,理想例如:一鹵素,一低級 烷基,一 C Ο 2 Η,或—C〇2 —低級烷基者。 本發明化合物(I )中做爲R 6之例者以一 C〇2 η, 經濟部智慧財產局員工消費合作社印製 —C (ΝΗ) ΝΗ2,— NHC (ΝΗ) ΝΗ2 或被取代亦 可之雜環者宜,更以一C〇2H,一 C (ΝΗ) ΝΗ2,— N H C ( Ν Η ) Ν Η 2或四唑基者爲較佳。R 2之例以低級 院基者宜。 R 5之例爲環烷基,3位具有取代基之苯基等者,做爲 該取代基之例者以鹵素,低級烷基者宜。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --8-=------- 經濟部智慧財產局員工消費合作祍印製 1262919 A7 一___„__^ B7 五、發明說明(7 ) R)體,(S)體之光學異構體。本發明包含此等所有之 光學異構體混合物,單離者。 本發明化合物更包含藥理學上可容許之前驅藥物°戶斤 謂藥理學上可容許之前驅藥物係指藉由加溶媒分解或於生 理學條件下具有可於本發明N Η 2,〇Η,C〇2 Η等中變 換之基的化合物者。做爲形成前驅藥物之基者如載於?『〇2· Med.,5 2 1 57-2 1 6 1 ( 1 985),「醫藥品之開發」(廣川書店’ 1 9 9 0年)第7卷分子設計1 6 3 — 1 9 8之基者例。 本發明化合物係依不同酸附加鹽或取代基種類亦有與 鹽基形成鹽者。做爲該鹽者爲製藥學上可容許鹽者,具體 例如:鹽酸,溴化氫酸,碘化氫酸,硫酸,硝酸,磷酸等 無機酸,蟻酸,醋酸,丙酸,草酸,丙二酸,琥珀酸,延 胡索酸,馬來酸,乳酸,蘋果酸,酒石酸,檸檬酸,甲磺 酸,乙磺酸,天冬胺酸,谷胺酸等有機酸之酸附加鹽,鈉 ,鉀,鎂,鈣,鋁等之無機鹽基,甲胺,乙胺,乙醇胺, 賴胺酸,鳥胺酸等與有機鹽基之鹽,銨鹽等例。 本發明更包含本發明化合物(1 )及其鹽之各種水和 物,溶媒和物及結晶多形物質者。 (製造方法) 本發明化合物及其製藥學上可容許鹽係利用基於其:_ 本骨架或取代基種類之特徵後,適用各種公知合成法後q 製造之。此時,藉由官能基之種類將該官能基於原料_ φ 間體的階段下轉換成可轉化之基成適當保護基,亦即可_ ---------— II--訂·---I---- (請先閱讀背面之注意事項再填寫本頁)
1262919 ―- ____________ B7 五、發明說明(8 ) 易於該官能基上進行轉換者爲製造技術之效果者。必要時 去除保護基後,可取得所期待之化合物。做爲此官能基之 例者如:氫氧基,羧基等,做爲此等保護基之例者如: Greene 及 Wuts所著作之「Protective Groupsin Organic Synthesis (第2版)所載之保護基例,只要因應適當條件 使用此等即可。 (1)第1製法
〇、X-FT
X-Rc (請先閱讀背面之注意事項再填寫本頁) (式中,L 1代表脫離基。以下相同。) 本製法係於胺基D[t D定衍生物(I I )中以一般式( I Ϊ I )所示之醯化劑做爲反應醯胺衍生物(I V ),製 造直接附與閉環反應之本發明化合物(I )之方法者。 經濟部智慧財產局員工消費合作社印製 L 1做爲所代表之脫離基者如:鹵素,醯氧基,烷氧基 碳氧基等之碳酸酯,甲磺醯氧基,對一甲苯磺醯氧基等有 機磺酸殘基例。又,與X R 6上之取代基呈一體之L 1,其 一般式(I I I )於分子內或分子間形成酸無水物(如: 戊二酸無水物等)亦可。 反應係於二氯甲烷,二氯乙烷,氯仿等鹵化烴基類, 苯’甲苯,二甲苯等芳香族烴基類,二乙醚,四氫呋喃(
T H F 氧陸圜等醚類,Ν,Ν-二甲基甲醯胺 -11 - 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 1262919
五、發明說明(9) DMF)等反應中,不 〜加熱下進行之。反應 衍生物(I I )與醯化 鹽基(三乙胺,吡啶, ’理想之無機鹽基(氫 氫化鈉’甲氧基鈉,第 ’可有利提昇反應順利 本製法亦可階段性 及閉環反應。此時,於 ,溫度’鹽基等條件。 又,原料化合物( 7號公報19一21頁 (2)第2製法 活性有機溶媒中或無溶媒下,冷卻 時,可以當量或過剩量之胺基吡旋 劑(I I I )使用之,理想之有機 4 — ( N,N / —二甲胺)吡啶) 氧化鈉,碳酸鉀)或金屬鹽鹽基( 3 - 丁氧基鉀等)之存在下反應者 進行之。 進行胺醯胺衍生物(I V )之單離 各反應中可適用與上記相同之溶媒 I I)係依w〇 9 7 / 1 9 0 7 所載之方法進行合成。 (請先閱讀背面之注意事項再填寫本頁) R1
經濟部智慧財產局員工消費合作社印製 本製法係藉由水解羧酸酯體之本發明化合物(I a ) 後,製造具有羧基之本發明化合物(I b )之方法者。反 應可依水解之常法進行,例如可適用上述「Protective Groups in Organic Synthesis(第2版)」之竣基保護反應等 所載之方法。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1262919 Α7 Β7 五、發明說明( (3)第3製法 10 (la)
R
FT
X,、Rd 經濟部智慧財產局員工消費合作社印製 (式中,R a代表雜環基 本製法係使藉由本發 化合物(I c )更藉由氫 物(I d )之方法者。 本發明化合物(I c 例如:載於日本化學會編 2 0 卷(1 9 9 2 年)( 本發明化合物(I d )氯化亞硫醯等反應所取 甲磺醯基或氯化對一甲苯 與求核該藥化合物(V ) I c )附與光延反應者亦 芳香族烴基類,醚類,D 無溶媒下於冷卻〜加熱下 另一爲過剩量之化合物( 機鹽基,無機鹽基或金屬 利順利進行之。 °以下相同 明化合物( 還原之本發明 氧基之取代反應製造本發明化合 )之製造可利用酯還原之常法, 「實驗化學講座(第4版)」 九善)等之方法。 )之製造係藉由與化合物(I c 得之烷基氯化物衍生物或與氯化 磺醯等反應所取得之有機磺酸酯 反應後被製造之。或使化合物( 可取得。反應係以鹵化烴基類, M F等反應中不活性有機溶媒或 進行之。反應時,可使用當量或 I c )與化合物(V )者,於有 鹽鹽基之存在下對於反應較可有 (請先閱讀背面之注咅?事項再填寫本頁) 一裝 i*----r--訂---- 本紙張尺度適用中國國家標準(CNS)A4規格(210 x 297公釐) 1262919 A7 B7 五、發明說明( (4)第4製法 11
R丨 R
本製法係將由本發 f ) , ( I g ), (Ih) 明化合物(I e )之本發明化合物 及(I η )藉由上述經路進行製造 (請先閱讀背面之注意事項再填寫本頁) 之方法 本 由脫水 本化學 年)( 本 與疊氮 化烴基 D M F 卻〜加 剩量或 胺鹽酸 氫氧化 在下進 者。 發明化合 後製造之 會編「實 九善)等 發明化合 化鈉等氮 類,芳香 ,水等於 熱下進行 當量之疊 鹽,鹽酸 鈉,氫氧 行反應者 訂---- 經濟部智慧財產局員工消費合作社印製 物(I 。反應 驗化學 所記載 物(I 雜化物 族烴基 反應中 之。反 氮化物 ,氯化 化鉀, 較有利 f)可使本發明化 可利用脫水反應之 講座(第4版)2 之方法者。 g )可藉由本發明 鹽相互反應後製造 類,醚類,甲醇, 於不活性溶媒中, 應時針對化合物( 鹽,於酸(醋酸, 鋁等),或鹽基( 甲氧基鈉,第3 — 合物(I e )藉 常法,例如:曰 〇卷(1 9 9 2 化合物(I f ) 之。反應係以鹵 乙醇等之醇類, 或無溶媒下,冷 I f )可使用過 三氟醋酸,三乙 口比卩定,三乙胺, 丁氧基鉀等)存 於反應之順利進行。 本紙張尺度適用中國國家標準(CNS)A4規格(210 χ 297公釐) 1262919 A7 _ B7 _ 五、發明說明(12 ) 本發明化合物(I h )可藉由本發明化合物(I f ) 與氨,氯化銨等銨鹽,鈉醯胺等金屬醯胺等相互反應後製 造之。又,藉由化合物(I f )與氯化氫反應後取得之氯 化亞胺基與藉由與氯化銨等之銨鹽相互反應後製造者亦可 。反應係於鹵化烴基類,芳香族烴基類,醚類,醇類, D M F,水等之反應中,存在不活性溶媒,或無溶媒下, 冷卻〜加熱下,常壓〜加熱下進行之。 又,本發明化合物(I e )可使本發明化合物(I b )藉由附與醯胺化反應進行製造之。 反應係使化合物(I b )於縮合劑(如:二環己羧二 亞胺(DCC),二異丙羧二亞胺(DIPC),:[一乙 基一 3 — (3 —二甲胺丙基)羧二亞胺(WSC) ,1, 1 一碳基雙一 1H —咪π坐(CD I )等)存在下,不同 情況下,更於添加劑(如:正一羥基琥珀亞胺( Η Ο N s u ) ,1 一羥基苯並三唑(H〇Bt)等之存在 下,藉由與氨縮合後進行之。另外,化合物(I b ) —旦 與上述添加劑之活性酯體單離後,亦可與氨進行縮合。做 ------^---.---裝 i*----^---訂--------- (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 F 使 Μ 合 D混 ’ 上 類以 474^1 一一彐11 基種 烴 2 化可 鹵亦 類用 醚使 ’ 獨 類單 基可 烴媒 族溶 香等 芳此 • · ο 如例 者等 媒啶 。 溶吡之 爲,用 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1262919 Α7 Β7 五、發明說明( (5)第5製法 13 (lb)
R
(VI)
R
X .NH0 b )製造具 經濟部智慧財產局員工消費合作社印製 本製法係由具有羧基之本發明化合物( 有胺基之本發明化合物(I i )之方法者。 化合物(V I )係藉由與化合物(I b )所取得之酸 無水物等羧基之反應性衍生物與疊氮化鈉等疊氮化物鹽相 互反應或藉由疊氮化二苯磷醯(D P P A )法取得酸疊氮 之curtius轉位,或藉由該化合物(I e )之Hofmann轉位等 所取得之異氰酸酯體與酒精化合物進行反應後可製造之。 反應係於鹵化烴基類,芳香族烴基類,醚類,D M F 等反應中存在有機溶媒或無溶媒,冷卻〜加熱下進行之。 反應時,針對化合物(I b )可使用當量或過量之酒精。 本發明化合物(I i )係使化合物(V I )藉由上述 「Protective Group sin Organic Synthesis(第 2 版)」戶斤載之 胺基之胺基甲酸酯型保護基之去除反應等所製造之。本反 應亦可不單離化合物(V I )繼續上述反應者。 (6)第6製法
R
X NK
R
Η ΝγΝΗ2 ΝΗ (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1262919 A7 B7 五、發明說明(15) (請先閱讀背面之注意事項再填寫本頁) 活性,ϊ V型P E E之呼吸道疾病(如:支氣管氣喘(含 阿托品性氣喘),慢性支氣管炎,肺炎性疾病,成人呼吸 急迫症候群(A R D S )等)之預防,治療劑有效者。特 別可期待做爲支氣管氣喘之預防,治療藥者。 本發明化合物更做爲I V型P D E相關之公知之其他 病症如:有關細胞分裂素(IL 一 1,IL 一 4,IL 一 6及T N F (腫瘤壞死因子))等病症(如:慢性風濕性 關節炎,潰瘍性大腸炎,慢性腸炎,敗血症,敗血性休克 ,內毒素性休克,葛蘭氏陰性菌性敗血症,心跳急促休克 症候群,腎炎,肝炎,感染(細菌及病毒),循環不全( 心不全,動脈硬化,心肌梗塞,腦中風)等)等等之預防 ,治療藥亦有效者。又,本發明化合物由於不易藉由藥物 代謝酵素被代謝,因此,做爲具有良好體內動態之持續性 藥劑爲有效者。 本發明化合物之有用性藉由以下試驗被確定之。 試驗例1 I V型P D E阻礙活性 經濟部智慧財產局員工消費合作社印製 1 )含有I V型P D E之溶液係由如下實驗鼠心室肌 所精製者。於醚麻醉下摘出雄性之w1Sta實驗鼠之心臟以生 理食鹽水進行洗淨後,分離心室。將分離之心室以剪刀細 切後,將此於含 1 % Protease Inhibitor CockTalL for Mammalian Cell Extracts (SIGMA)之緩衝液 A ( 2 0 m Μ Bis-Tris,50mM醋酸鈉,2mM EDTA,5mM2 —氫 硫基乙醇,2 mM benzamidene,0 · 〇 5mM苯基—甲基 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1262919 A7 B7 五、發明說明(16) 一硫醯一氟化物,p Η 6 · 5 )進行懸浮後,藉由 polythoron (多钍射氣)破壞細胞,藉由超遠心( 1 0 0,0 0 0 G,6 0分鐘,4 °C )取得可溶性畫分。 (請先閱讀背面之注意事項再填寫本頁) 2 )於以緩衝液A被平衡化之2 · 6 X 1 〇 c m Q瓊 脂糖柱體中,塡入所取得之可溶性晝分。順便將該柱體以 1 2 0 〇 之緩衝液A進行洗淨後,去除未結合蛋白。於 該柱體中,使結合之蛋白利用含有〇 · 〇 5〜1 · 0 〇 Μ 醋酸鈉之線形分級液之7 5 0 緩衝液Α後進行溶出後, 回收1 1 0根7 畫分。針對存在c G Μ P及鈣/特異結 合蛋白質存在下,或非存在下所取得之各分畫c AMP代 謝P D E活性進行檢查。各畫分中具有c A Μ P之代謝活 性,且c G Μ Ρ或鈣/特異結合蛋白質存在下,使不受 c A Μ Ρ代謝活性影響之畫分做爲檢查I V型P D Ε阻礙 活性之貯存溶液使用之。
3 )試驗化合物係使所期待濃度以含有4 0 m Μ Tris— HC1 (ρΗ8·0) ,5mM氯化鎂,4 mM2 —氫硫基乙醇,1//M cAMP,1//C 經濟部智慧財產局員工消費合作社印製 〔3 Η〕c A Μ P及I V型P D E貯存溶液之反應混合液中 ,3 0°C下進行反應1 0分鐘。於反應液中加入半量之 1 8mM硫酸鋅,含5//M 3 -異丁基一 1—甲基黃質 (I Β Μ X )之2 0 m g / 聚賴胺酸塗佈釔矽酸鹽, S Ρ A玻璃粉(A m e r s h a m )懸浮液後’停止反應後,進行 測定放射活性。 I C 5 〇係以I V型P D E之代謝活性做爲5 0 %阻礙 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 1262919 / \ / 一 B7 五、發明說明(17) 之試驗化合物濃度,針對各化合物進行算取之。 應用該試驗法與W〇 9 7 / 1 9 0 7 8公報所載之 方法後,同樣測定I ,I I ,I I I及V型P D E阻礙活 性。 該阻礙活性測定試驗之結果確定本發明實施例化合物 對於IV型PDE具有〇· 095〜1 InM之I c5 ◦値 者。 試驗例2 使用肝微粒體之in vitro藥物代謝試驗 1 )人體及實驗鼠肝微粒體懸浮液(人體微粒體: Xenotech公司,實驗鼠微粒體·· charseliva公司)其蛋白質 量以1 0 0 m Μ N a - Κ磷酸緩衝液(ρ Η 7 . 4 )稀 釋爲0 · 5 m g / 。於此1 〇 〇 m£懸浮液中’加入2 // 1之試驗化合物溶液(1 0 // g / 乙腈溶液), 500// 1之2〇〇mM Na— K磷酸緩衝液(pH 7.4) ,50μ1 之 ImM EDTA-NaOH ( pH7 · 4)及2〇〇’// 1之精製水後,做成0 · 〇5 m g / 之基質溶液(反應溶液中之濃度:肝微粒體(蛋 白量),2 0 n g /J試驗化合物,1 〇 0 m Μ N a〜 K磷酸緩衝液,〇 · 1 m Μ E D T A — N a〇Η )。 2)混合42mg之NADP,5m£之100m:M:¾ 萄糖—6 -憐酸酶(G6 Ρ )及之1 0 OmM MgC 12之後,加入57// 1之G6P脫氫酵素(約 1750U/5mg/mi),進行調製NADPH生成 (請先閱讀背面之注意事項再填寫本頁} --------訂---------線- 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) -20- 經濟部智慧財產局員工消費合作社印製 1262919 A7 ___El_____ 五、發明說明(18 ) 系。於3 7 °C下進行加溫5分鐘後,供與使用前進行冰冷 之。 3 )將9 0 0 // 1之基質溶液於3 7 °C下進行預恆溫 5分鐘後,加入100//1之NADPH生成系,37°C 下反應10分鐘,2 0°C,3 0分鐘。加入22之醋酸乙 酯後停止反應後,進行冰冷。另外,對照樣品係加入2 4 醋酸乙酯後,再加入100/z 1之NADPH生成系後進 行調製(反應0分鐘)。 4 )於反應液中加入1 〇 〇 μ 1之一定濃度內部標準 物質(乙腈溶液)’ lm£之〇 · 5M磷酸及22之醋酸乙 醋後’振動1 0分鐘。於2 5 0 0 r p m進行離心分離 1 0分鐘後,分取醋酸乙酯層後使蒸發乾固後,將殘渣溶 於Η P L C之1 〇 〇 # 1移動相溶媒。下記條件下,約 1 2分鐘溶出試驗化合物,約1 6分鐘溶出內部標準物質 。(Η P L C測定條件移動相:乙腈/ 2 0 m Μ醋酸銨 =2 : 3 ( ν / ν ),柱體:Discovery RP Amide C16,4.6 x 35mm( SUPELC0公司),流速:〇 · 8 i n,檢出 • UV286nm)。 5 )對照中對於試驗化合物頂點高度比(與內部標準 物貝之頂點筒度比)算出反應1 〇分鐘,2 〇分鐘,3 〇 分鐘後之頂點高度比之比例(殘存率)。 曰亥測定試驗結果證明實施例3,6,7,8之化合物 不受存在於肝微粒體中:P 4 5 〇藥物代謝酵素之代謝。 L本紙張尺度適用中國國(CNS)A4規格⑵G x 297公餐)-^------ I --------·1--裝--------訂---------線 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1262919 A7 ______B7 五、發明說明(19) 試驗例3 以I V型P D E阻礙活性做爲指標之經口吸收 性及體內動態評定試驗 爲評價抑制I V型P D E之本發明化合物經口吸收性 及體內動態如下所示進行試驗之。 1 ) 將懸浮〇 · 5 %甲基纖維素精製水之試驗化合 物以3 m g / k g經口投入7週齡雄性費歇爾實驗鼠中。 另外,對照群中同樣投入溶媒(〇 · 5 %甲基纖維素精製 水,3 / k g )。經口投服後,經時的由施與醚麻醉之 實驗鼠尾靜脈於肝素存在下進行採血後,依常法進行血漿 調製。 2 ) 將試驗化合物或溶媒由所投服之實驗鼠被調製 血漿做成最終濃度爲0 · 1 %後加入該試驗例1所示之 1 V型P D E測定系後,進行測定I v型P D E阻礙活性 〇 本試驗結果證明實施例3,6,7,8之化合物與比 較化合物相較後,較具良好之經口吸收性及持續性。(比 較化合物:4 一(3 —氯苯基)一 1 一乙基一 7 —甲基一 2 —羰基一1,2 —二氫—1,8 —萘啶)。 由上述1〜3試驗結果證明本發明化合物具有I V型 P D E阻礙活性,做爲相關I v型p d E病症之預防,治 療藥爲有效者。 以1種或2種以上本發明化合物或其鹽做爲有效成份 含有之製劑係利用一般製劑化所使用之載體,賦形劑,其 他添加劑進行調製者。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ------*---'---·裝·1·---hi 訂---------線· (請先閱讀背面之注意事項再填寫本頁) 1262919 A7
經濟部智慧財產局員工消費合作社印製 五、發明說明(2〇 ) 投用係藉由錠劑’九劑,膠囊劑,顆粒劑,散劑,液 劑等經口投服,或,靜脈注射,肌肉注射之注射劑,栓劑 ,經皮劑,經鼻劑,或吸入劑等非經口投用之任一形態均 可。投用量依其症狀,投用對象之年齡,性別等做適當決 疋’一般口服投用時,成人1天爲0·〇〇lmg/kg 至1 0 〇mg/k g者,此以1次或分2〜4次投服之。 另外,依不同症狀進行靜脈注射時,一般成人1次爲 〇· 001mg/kg〜l〇mg/kg之範圍,1日以 1次至複數次投與之。又,吸入時,一般成人爲1次 〇 · 0001mg/kg 〜lmg/kg,1 日 1 次至複 數次投與之,塗布時’爲〇·〇〇〇lmg/kg〜1 mg/kg之範圍者,1日以1次至複數次投與之。 做爲本發明之口服投用之固體組成物者如:錠劑,散 劑,顆粒劑等被使用之。此固體組成物中,其1個或更多 之活性物質與至少1個不活性賦形劑,如:乳糖,甘露糖 醇,葡萄糖,羥丙基纖維素,微結晶纖維素,澱粉,聚乙 烯吡咯烷酮,甲基矽酸鋁酸鎂等混合之。組合物亦可依常 法含有不活性添加劑,如:硬脂酸鎂等潤滑劑,羧甲基澱 粉鈉等崩散劑,溶解補助劑者。錠劑或九劑於必要時亦可 以糖衣或胃溶性或腸溶性塗佈劑進行被覆之。 經口投服之液體組成物係含有藥劑學上可容許乳劑, 液劑,懸浮劑,糖漿劑,馳劑等,含一般所使用之不活性 溶劑如:精製水,乙醇。此組成物除不活性溶劑以外,亦 可含有可溶化劑,濕潤劑,懸浮化劑類之補助劑,甜味劑 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ,—.—·—Γ—裝 i·----^—訂---------線 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1262919 A7 -----B7___ 五、發明說明(21 ) ,矯味劑,芳香劑,防腐劑。 做爲非經口投用之注射劑者爲含有無菌之水性或非水 性之液劑,懸浮劑,乳劑者。做爲水性溶劑者爲含有注射 用蒸餾水及生理食鹽水。非水性之溶劑例如:丙二醇,聚 乙二醇,橄欖油類之植物油,乙醇類之酒精類,聚山梨糖 醇8 0 (商品名)等。此組成物更可含有等張化劑,防腐 劑’濕潤劑,乳化劑,分散劑,安定化劑,溶解補助劑者 。此等經保留細菌濾器進行過濾,配合殺菌劑或照射後進 行無菌化者。又,此經製造無菌固體組成物後,亦可於使 用前溶於無菌水或無菌注射用溶媒後,懸浮後使用之。 〔發明實施之最佳形態〕 以下,藉由實施例進行本發明之具體說明,惟,本發 明並非僅限於此。 〔實施例1〕 於 20m£2 46 1mg4 — (3 —氯苯基)—3 —( 2 —氰乙基)一1—乙基一7 —甲基一1 ,8 —萘啶一2 (1 h ) —酮之乙醇一氯仿(1 : 1 )溶液中,以—7 8 °C,進行吹塑鹽酸氣體3 0分鐘,5 °C下進行攪拌1 8小 時後,餾去反應液。於取得固體中加入1 5 乙醇及 5〇5 m g醋酸氨後,攪拌9 0小時。餾去反應液後,將 殘渣以矽膠柱體色譜法(氯仿-甲醇-氨水)進行精製之 。取得之油狀物質加入0 · 4 4 Μ氯化氫一醋酸乙酯於 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) »--------^---裝--------訂---------線 (請先閱讀背面之注意事項再填寫本頁) 24 經濟部智慧財產局員工消費合作社印製 1262919 A7 _B7___ 五、發明說明(23 ) 行攪梓1 5小時。將反應液冷卻至室溫,加入lM鹽酸做 成酸性後’以醋酸乙酯進行萃取。以水及飽和鹽水洗淨有 機層,再以無水硫酸鎂進行乾燥後,飽去溶媒之後將取得 粗結晶由乙醇一水進f了再結晶後,取得2 9 5 m g之4 一 環己基一1 一乙基一7 —曱基一3 —〔2 —(1H —四口坐 —5 —基)乙基〕—1 ,8 —蔡啶一 2 (1H)—酮之黃 色結晶者。 〔實施例4〕 與實施例3同法進行合成4〜(3 —氯苯基)一 1一 乙基一 7 —甲基一3 —〔3— (1H —四π坐一 5 —基)丙 基〕—1,8 —萘啶—2 — (1H)—酮。 〔實施例5〕 與實施例3同法進行合成4 一(3 —溴苯基)一 1 一 乙基一7 —甲基一3 —〔2— (1H —四唑一 5 —基)乙 基〕1,8 -萘 β定—2 — (1H)—酮。 〔實施例6〕 於 15J之 2 · 70g 3 —〔4 — (3 -氯苯基) 一 1—乙基一 7 —甲基一2 —羰基一1 ,2 —二氫—1 , 8 —萘啶—3 —基〕丙酸乙酯的THF —甲醇(1 : 1) 溶液中加入1 5 m£ 1 Μ氫氧化鈉水溶液,於8 〇 °C油浴溫 度下進行2小時加熱下攪拌。冷卻至室溫,以1 M鹽酸水 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) i --------.1--裝--------訂---------線 (請先閱讀背面之注意事項再填寫本頁) 56- 1262919 A7 ___B7___ __ 五、發明說明(24 ) (請先閱讀背面之注意事項再填寫本頁) 溶液調成P Η 3後,以醋酸乙酯進行萃取。以飽和食鹽水 進行洗淨有機層,餾去溶媒。以矽膠柱體色譜法(氯仿一 曱醇)進行精製殘渣,更由二異丙醚-醋酸乙酯進行再結 晶後,取得1,27g 3 —〔4— (3 —氯苯基)—1 —乙基一7 —甲基—2 —羰基一 1 ,2 —二氫一 1 ,8 — 萘d定一 3 -基〕丙酸之無色結晶。 〔實施例7〕 經濟部智慧財產局員工消費合作社印製 於2〇m£2 · 34g3 —環己烷碳基一2 —乙胺一6 一甲基吡啶之T H F溶液中加入3 · 0 m«之氯化戊二酸單 乙酯,2 · 8 2之2,6 -魯替菌素後,於油浴溫度6 0 t下進行加熱攪拌1小時。冷卻至室溫後,加入水後’以 醋酸乙酯進行萃取。以3 Μ鹽酸,飽和小蘇打水,以飽和 食鹽水進行洗淨,以無水硫酸鎂進行乾燥。餾去溶媒取得 之2 0 m£殘渣乙醇溶液中加入1 · 0 0 g甲氧基鈉後,進 行加熱逐流1小時。更於反應溶液中加入2 0 m£ 1 Μ氫氧 化鈉水溶液進行加熱逐流1小時。冷卻至室溫後,加水, 以1 Μ鹽酸中和之,以醋酸乙酯進行萃取。再以飽和食鹽 水進行洗淨有機層後,以無水硫酸鎂進行乾燥之,餾去溶 媒後由乙醇-水將取得之殘渣進行再結晶後,取得7 6 4 mg之3 —(4 一環己基一1—乙基一7 —甲基一 2 —羰 基一 1 ,2 —二氫一 1,8 -萘d定一 3 -基)丙酸之無色 結晶。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) --- 1262919 A7 B7 五、發明說明(25) 〔實施例8〕 將混合4 0 0 m g之3 -( 1 一乙醯哌啶一 4 一基) —4 一(3 —氯苯基)—1—乙基—7 —甲基—1 ,8 — 萘D定—2 —(1H) -酮’ 5m£乙醇,及5m£6M鹽酸水 溶液之混合溶液進行加熱逐流1 5小時。濃縮反應液後, 加入飽和小蘇打水後以氯仿萃取之。以水及飽和食鹽水洗 淨有機層後,餾去溶媒。以矽膠柱體色譜法(氯仿-甲醇 -氨水)進行精製殘渣,取得黃色油狀物溶於5 m£之甲醇 後,加入1 4 5 m g延胡索酸之甲醇溶液。將餾去溶 媒後取得之殘渣由乙醇-醋酸乙酯進行再結晶後,取得 187mg之4一(3 —氯苯基)一1—乙基一 7 —甲基 —3 —(哌啶—4 —基)—1,8 —萘啶一2 ( 1 Η )— 酮-延胡索酸鹽微黃色結晶。 〔實施例9〕 經濟部智慧財產局員工消費合作社印製 於2 0〇g之4 — (3—氯苯基)_1 一乙基一3 — (2 —羥乙基)一7_甲基—1 ,8 —萘啶一2 (1H) 一酮,1 · 02之三乙胺,及20m£之THF混合物中, 冰冷下,滴入0 · 5 2之氯化甲磺醯,室溫下攪拌3 0分 鐘。反應液中加水,以醋酸乙酯進行萃取之。以1 Μ鹽酸 ,飽和小蘇打水,飽和食鹽水依序洗淨有機層,以無水硫 酸鎂進行乾燥之。於2 0 之餾去溶媒後取得殘渣之 THF溶液中加入1 · 02三乙胺,1 · 〇m£六氫異菸酸 乙酯,及5 0 0 m g之碘化鉀後,於油浴溫度6 0 °C下, no (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 經濟部智慧財產局員工消費合作社印製 1262919 A7 ---- B7 五、發明說明(26 ) 進行加熱攪拌一晝夜。冷卻至室溫後,加入水以醋酸乙醋 進行萃取之◦以飽和食鹽水洗淨有機層,以無水硫酸鎂進 行乾燥之。將餾去溶媒取得之殘渣以矽膠柱體色譜法(氯 仿一甲醇)進行精製後,取得1 · 7 0 g之酯體。與以下 實施例6同法取得593 mg之1— {2 —〔4一(3 — 氯本基)—1 一乙基—7 —甲基—2 —鑛基一 1 ,2 —二 氫一 1,8 —萘卩定一 3—基〕乙基} I—帳D定一 4 ~~羧酸無色 結晶。 實施例1〜9之化合物結構及物理化學性數據示於表 1 〇 原料化合物之製法如參考例所示。又,依W 0 9 7 /19078號公報參考例45,48及51所載方法分 別製造3 —(3 -氯苯甲醯)—2 —乙胺一 6 —甲基吡啶 ,3 — (3 —溴苯甲醯)一 2 —乙胺一 6 —甲基吡啶及3 一環己烷羰基一 2 -乙胺一 6 —甲基吡啶。 〔參考例1〕 於4 一氰基丁酸及三乙胺之T H F溶液中,冰冷下加 入氯化二甲基乙醯後,室溫下攪拌1小時。由反應液濾別 不溶物,於餾去溶媒後取得殘渣中加入3 -環己烷羰基-2 -乙胺一 6 —甲基吡啶後,1 5 0 t:下進行攪拌1 4小 時。反應液冷卻至室溫,加入醋酸乙酯,藉由分液洗淨後 精製取得之生成物溶於乙醇後,加入甲氧基鈉進行逐流1 小時。以下,依常法進行後處理,精製後,取得無色固體 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ——’-—--------訂--------- (請先閱讀背面之注意事項再填寫本頁) 1262919 經濟部智慧財產局員工消費合作社印製 A7 B7 27 五、發明說明() 之3 — (2 —氰基乙基)一 4 一環己基一 1 一乙基—7 一 甲基一1 ,8 —萘啶—2 (1H)—酮。MS : 324。 〔參考例2〕 與參考例1相同,取得微黃色固體之4 一( 3 一氯苯 基)一3 —(2 —氰乙基)一1—乙基—7 —甲基一1 , 8 —萘啶一 2 (1H)—酮。MS : 352。 〔參考例3〕 與參考例1同法,合成4 一(3 -溴苯基)一 3 -( 2 —氰乙基)一1〜乙基一7 —甲基一1 ,8 —萘啶一2 (1 Η )—酮。 M S : 3 9 6。 〔參考例4〕 將(1 一乙醯哌啶一 4 一基)醋酸乙酯,乙醇及1 Μ 氫氧化鈉水溶液之混合物於室溫下進行反應4小時後取得 (1 一乙醯哌啶一 4 一基)醋酸於甲醇中以甲氧基鈉進行 處理。取得之粗生成物於T H F中,氯化三甲基乙醯與室 溫下反應2小時。以下,與參考例1同法處理後,取得微 黃色固體之3 — ( 1 -乙醯基丨哌陡—4 —基)一 4 — (3 —氯苯基)一1—乙基—7-甲基一 1 ,8 —萘啶—2 ( 1 Η )-酮。 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 丨丨:---:---.---Φ裝! (請先閱讀背面之注意事項再填寫本頁)
經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) 1262919 A7 ____B7___ 五、發明說明(28 ) 〔參考例5〕 於3 —〔4一(3 -氯苯基)一 1 一乙基—7 -甲基 一 2 -羰基一 1 ,2 —二氫—1 ,8-萘啶一 3 —基〕丙 酸之二氧陸圜溶液中加入D P P A及二乙胺,進行加熱逐 流2小時。將反應液冷卻至室溫,加入乙醇,再進行加熱 逐流1 4小時。反應液減壓濃縮後,取得之殘渣中加入醋 酸乙酯,分液洗淨後進行精製取得之生成物溶於乙醇,加 入6 Μ氫氧化鈉水溶液後,進行加熱逐流2天。以下,依 常法進行後處理,精製後,取得微黃色油狀物之3 -( 2 一胺基乙基)一 4 一(3 -氯苯基)一1 一乙基一7 —甲 基一 1,8 -萘啶一 2 _( 1 Η ) -酮。此化合物於乙醇 中做成延胡索酸鹽,取得微褐色固體之1延胡索酸鹽, 1 . 5 乙醇和物。ΜΡ : 171 — 175。 〔參考例6〕 與實施例7同法取得之4 一〔 4 _( 3 -氯苯基)一 1—乙基一7 —甲基一 2 —羰基一1 ,2 —二氫一1 ,8 一萘啶一 3 -基〕丁酸之THF溶液中加入滴氯化乙二醯 及1滴D M F後,室溫下進行攪拌之。於冰冷下濃氨水之 T H F溶液中滴入反應液後,進行攪拌3 〇分鐘。以下, 依常法進行後處理,精製後,取得4 一〔 4 一( 3 -氯苯 基)一 1 一乙基一7 —甲基一乙羰基一1 ,2 一二氫—1 ,8 -萘π定一 3 -基〕丁醯胺。所取得化口物之~^氯乙火兀 溶液中加入1滴吡啶,氧基氯化磷,D M F後’室溫下進 ^---- ------'------裝 i·----r —訂---------線 (請先閱讀背面之注意事項再填寫本頁) 1262919 經濟部智慧財產局員工消費合作社印製 A7 B7 五、發明說明(29) 行攪拌之。以下,依常法進行後處理,精製後,取得4 -(3 -氯苯基)一 3一(3 —氰基丙基)一 1 一乙基一 7 —基—1,8 —萘啶—2 (1H)—酮。NMR1 : 6-90 j=8-2Hz) ,4.67(2 H,Q,J = 7.1Hz),1·7- 2·1〇(2Η, m ) 〇 〔參考例7〕 以6 0%氫化鈉處理3 — (3 -氯苯甲醯一 1 一 2 -乙胺- 6 -甲基吡啶之D M F溶液後,加熱下與氯化戊二 酸單乙酯反應之。以下,依常法進行後處理,精製之後’ 取得4 一 {Ν —〔3 —(3 —氯苯甲醯)一 6 —甲基吡聢 一 2 —基〕一 Ν —乙基胺基甲醯} 丁酸乙酯。所取得化合 物於乙醇中同時與甲氧基鈉於加熱下進行反應後,於反應 液中更加入濃硫酸加熱下進行反應2天。以下,依常法進 行後處理,精製後,取得3 -〔 4 一( 3 —氯苯基)一 1 —乙基一7 —甲基一2 —羰基一1 ,2 —二氫一1 ,8 — 萘啶一 3基〕丙酸乙酯。MS : 399。 〔參考例8〕 與實施例7同法取得之2 -〔 4 一( 3 -氯苯基)一 1 一乙基一 7 —甲基—2 —鑛基一1 ,2 —二氫一 1 ,8 一萘啶一 3 一基〕醋酸之甲醇溶液中加入濃硫酸後,進行 加熱逐流1晝夜。以下,依常法進行後處理’精製後’取 本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公爱Γ ----.---.---#裝 i’---l·--訂---------線 (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 1262919 Α7 Β7 五、發明說明(30) 得3 -〔4 — (3 —氯苯基)一1 一乙基一 7 —甲基—2 一碳基一 1 ’ 2 —二氫一 1 ’ 8 —萘D定一 3 —基〕醋酸甲 酯。所取得化合物之T H F溶液中加入氫化硼鈉。於加熱 逐流下滴入甲醇,再進行加熱逐流2小時。以下,依常法 進行後處理’精製後,取得4 一( 3 -氯苯基)一 1 一乙 基一 3 -(2 —羥乙基)—7 —甲基一2 —羰基一 1 ,2 —二氫一 1,8 -萘啶—2 (1Η)—酮。NMR1·· 6.92(!H,d,J = 8.2Hz) ,4.67(2 H,q,j-7.〇Hz) ,3.74(2H,t,卜 5 · 8 Η z ) ° 該參考例及表1中之略號爲以下所代表之。E x :實 施例號碼,D a t :物理化學性數據(M S : F A B - MS) ( Ivl + Η ) +,Μ P :融點(°C ) ,d e c :分解, NMR1 : CDCl3 中1 HNMR 之特徵頂點 5 (PPm )),nMR2 : DMS〇一d6中之1 HNMR特徵頂點 8 ( p p m ) ) ’ s a 1 :鹽及其所含有溶媒(空欄: f r e e體,f u m ••延胡索酸鹽,H C 1 :鹽酸鹽, Η 2〇:水合物)’ s y η ••製造法(數字與所製造實施例 號碼所示者相同)° ----------r-----------訂---------"^^1 (請先閱讀背面之注意事項再填寫本頁) 本紙張尺度適用+國國家標準(CNS)A4規格(2i0 χ 297公釐) -33- 1262919 A7 _B7 五、發明說明(31 )
經濟部智慧財產局員工消費合作社印製
Ex R5 X-R6 Dat Sal 1 ^Cl \^γΝΗ2 ΝΗ ΜΡ :228-230 ; NMR2:8.83 (2Η5 s)5 8.60 (2Η, s)5 4·54 (2Η,q) HC1 2 ^Cl νη2 1 ΝΗ MS : 384 ; NMR2 : 9.57 (1H, brs)5 6.95-7.52 (3H,brs),4.56 (2H,q) HC1 H20 3 ό MP : 207-209 ; MS : 367 4 Η MP : 155-158 ; NMR2 : 15.86 (1H5 s), 7.10 (1H, d,J=8.1 Hz),4.52 (2H5 q,J=7.1 Hz) 5 άΒΓ MP : 194-196 ; MS : 439 6 ά〇, -(ch2)2c〇2h MP : 149-151 ; NMR1:6.93 (1H, d5 J=8.3 Hz), 2.69-2.81 (2H,m),2.53-2.60 (2H,m) 7 ό -(ch2)2c〇2h MP : 155-156 ; NMR1 : 4.64 (2H, q5 J=7.0 Hz)? 1.39-1.78 (10H; m)5 1.33 (3H,t5 J=7.0 Hz) 8 ^Cl ·Χ?ΝΗ MP: 225-227; NMR2:7.08 (1H,d,J=8.3 Hz), 4.51 (2H? q? J=6.8 Hz), 1.50-1.62 (2H, m) fum 9 ^Cl L"^co2h \ MP : 142-146 ; NMR2 : 7.08 (1H, d? J=7.8 Hz), 4.52 (2H? q? J=6.8 Hz), 2.04-2.14 (1H, m) i!——.---- |丨#裝 i (請先閱讀背面之注意事項再填寫本頁)
本紙張尺度適用中國國家標準(CNS)A4規格(210 X 297公釐) ^4
Claims (1)
1262919 ABCD 六 申請專利範圍 —— 丨 〜一一—........... …—…:"〃—〜,丨89 1 22260號專利申請案本p 4丨卜| '中文申請專利範圍修正本 〜·-一'〜…"^-—-〜一J 民國95年5月19日修正 .一種萘啶衍生物及其製藥學上可容許鹽’其特徵 式 般 如 係
R (請先閱讀背面之注意事項再填寫本頁) 經濟部智慧財產局員工消費合作社印製 ( 式 中之記 號如 下 y R 1 :C 1 一 C 6 烷 基, R 2 :C 1 — C 6 院 基, R 3 ,R 4 : Η, R 5 :C 3 — C 8 環 烷基,或可被鹵素 取代 之苯基, X 鍵結或 C 1 一 C 6伸烷基, R 6 :可被由R 10 選出之基所取代之 哌啶 、四口坐、 一 C 〇2 Η 、 一 C (Ν Η ) Ν Η 2 或 Ν H C ( Ν Η ) Ν Η 2, R 1 0 : — C 〇 2 Η, 其中,X爲鍵結時,R6爲可被由Ri°選出之基所取 代之哌啶)。 2 .如申請專利範圍第1項之萘啶衍生物及其製藥學 上可容許鹽,其中該R2爲Cl— C6烷基,R6爲可被由 R 1 Q選出之基所取代之哌啶、四唑、一C〇2 Η、 本紙張尺度適用中國國家標準(CNS ) Α4規格(210父297公董1 ^ 1262919 A8 B8 C8 D8 六、申請專利範圍 —C (NH) NH2 或—NHC (NH) NH2 者。 (請先閱讀背面之注意事項再填寫本頁) 3 .如申請專利範圍第1項之萘啶衍生物及其製藥學 上可容許鹽,其中該R 5爲環己基或被鹵素所取代之苯基, R 6爲被C〇2 Η所取代之哌啶、四唑、一C〇2 Η, —C (ΝΗ) ΝΗ2,或—NHC (ΝΗ) ΝΗ2 者。 4 .如申請專利範圍第1項之萘啶衍生物及其製藥學 上可容許鹽,其中該萘啶衍生物及其製藥學上可容許鹽係 選自3— (2 —脒基乙基)—4 一(3 -氯苯基)一 1一 乙基一7 —甲基一1 ,8 —蔡B定一2 (1H)—醒,4 — (3 —氯苯基)一1 一乙基一3 —(2 —胍基乙基)一 7 一甲基—1 ,8 —萘啶一 2 (1H) —酮,4 —環己基一 1—乙基一7 —甲基一3 —〔2 — (1H —四哇一5 —基 )乙基〕一1 ,8 —萘啶一2 — ( 1H)—酮,4 — (3 —氯苯基)一1—乙基一7 —甲基一 3 —〔3—( —四唑一5 —基)丙基〕一 1 ,8 —萘啶—2 ( 經濟部智慧財產局員工消費合作社印製 1H)—酮,4 — (3 —溴苯基)一1—乙基—7 —甲基 —3 — 〔2— (1H — 四哗一5 —基)乙基〕一1 ,8 — 萘 π定—2 (1H)—酮,3 —〔4 — (3 —氯苯基)一1 —乙基—7 —甲基一2 —羰基一1 ,2 —二氫一 1 ,8 — 蔡啶一 3 —基〕丙酸,3 —(4 —環己基—1—乙基一 7 —甲基—2 —羰基一1 ,2 —二氫一1 ,8 —萘啶一3 — 基)丙酸,4 一(3 —氯苯基)—1—乙基一 7 —甲基一 3 —(哌啶—4 —基)—1 ,8 —萘啶—2 (1H)—酮 ,及 1— {2 —〔4 — (3 —氯苯基)—1—乙基一7 — 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -2- ABCD 1262919 六、申請專利範圍 甲基一2 —羰基一1 ,2 -二氫一1 ,8 —萘啶—3 —基 〕乙基}哌啶一 4 一羧酸所成群中者。 5 · —種I V型磷酸二酯酶阻礙劑之醫藥組成物,其 特徵係如申請專利範圍第1項之萘啶衍生物及其製藥學上 可容許鹽以及製藥學上可容許載體所組成者。 ------------ (請先閱讀背面之注意事項再填寫本頁) 訂 經濟部智慧財產局員工消費合作社印製 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) -3-
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP30254499 | 1999-10-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
TWI262919B true TWI262919B (en) | 2006-10-01 |
Family
ID=17910254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW089122260A TWI262919B (en) | 1999-10-25 | 2000-10-23 | Naphthyridine derivative |
Country Status (16)
Country | Link |
---|---|
US (1) | US6740662B1 (zh) |
EP (1) | EP1225173B1 (zh) |
KR (1) | KR100699395B1 (zh) |
CN (1) | CN1148369C (zh) |
AR (1) | AR029185A1 (zh) |
AT (1) | ATE305470T1 (zh) |
AU (1) | AU779081B2 (zh) |
BR (1) | BR0014981A (zh) |
CA (1) | CA2385178A1 (zh) |
DE (1) | DE60022893T2 (zh) |
ES (1) | ES2250200T3 (zh) |
MX (1) | MXPA02004122A (zh) |
PL (1) | PL354600A1 (zh) |
RU (1) | RU2240322C2 (zh) |
TW (1) | TWI262919B (zh) |
WO (1) | WO2001030779A1 (zh) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060046999A1 (en) * | 2002-03-14 | 2006-03-02 | Cristina Alonso-Alija | Monocyclic aroylpyridinones as antiinflammatory agents |
EP1660087A2 (en) * | 2003-07-22 | 2006-05-31 | Janssen Pharmaceutica N.V. | Quinolinone derivatives as inhibitors of c-fms kinase |
ES2378374T3 (es) * | 2003-11-20 | 2012-04-11 | Astellas Pharma Inc. | Inhibidores de la PDE 4 para el tratamiento de la cistitis intersticial |
TW200726767A (en) * | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
EP2258358A3 (en) | 2005-08-26 | 2011-09-07 | Braincells, Inc. | Neurogenesis with acetylcholinesterase inhibitor |
EP2275095A3 (en) | 2005-08-26 | 2011-08-17 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation |
JP2009512711A (ja) | 2005-10-21 | 2009-03-26 | ブレインセルス,インコーポレイティド | Pde阻害による神経新生の調節 |
CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
PL1992622T3 (pl) * | 2006-02-21 | 2012-01-31 | Eisai R&D Man Co Ltd | Pochodna 4-(3-benzoiloaminofenylo)-6,7-dimetoksy-2-metyloaminochinazoliny |
US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
JP2009536667A (ja) | 2006-05-09 | 2009-10-15 | ブレインセルス,インコーポレイティド | 5ht受容体介在性の神経新生 |
AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
WO2007135026A2 (de) * | 2006-05-24 | 2007-11-29 | Boehringer Ingelheim International Gmbh | Substituierte pteridine als therapeutika |
KR20090064418A (ko) | 2006-09-08 | 2009-06-18 | 브레인셀즈 인코퍼레이션 | 4-아실아미노피리딘 유도체 포함 조합물 |
US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
WO2008071964A1 (en) * | 2006-12-15 | 2008-06-19 | Astrazeneca Ab | Naphthyridine bactericides |
EP2123641A4 (en) * | 2007-02-16 | 2011-06-22 | Eisai R&D Man Co Ltd | CRYSTAL, AMORPHOUS FORM AND METHYL N-Ý3- (6,7-DIMETHOXY-2-METHYLAMINOQUINAZOLINE-4-YL) PHENYLENE TEREPHTALIC ACID SALT |
WO2009025239A1 (ja) | 2007-08-17 | 2009-02-26 | Eisai R & D Management Co., Ltd. | 新規外用剤 |
ATE538102T1 (de) * | 2007-08-17 | 2012-01-15 | Eisai R&D Man Co Ltd | Verfahren zur herstellung eines chinazolinderivats |
WO2009088054A1 (ja) | 2008-01-11 | 2009-07-16 | Astellas Pharma Inc. | 精巣の疼痛又は不快感行動及び頻尿併発モデル動物 |
BRPI0915273B1 (pt) | 2008-11-11 | 2021-08-03 | Je Il Pharmaceutical Co., Ltd | Derivado tricíclico ou seus sais farmaceuticamente aceitáveis e seus métodos de preparação |
WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
US10731199B2 (en) * | 2011-11-21 | 2020-08-04 | Advanced Liquid Logic, Inc. | Glucose-6-phosphate dehydrogenase assays |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
BR112020005934A2 (pt) * | 2017-09-28 | 2020-10-06 | Nanjing Transthera Biosciences Co., Ltd. | inibidor de pde9 e uso do mesmo |
CN111471059B (zh) * | 2019-01-23 | 2022-12-02 | 药捷安康(南京)科技股份有限公司 | Pde9抑制剂及其用途 |
TWI816026B (zh) * | 2019-03-08 | 2023-09-21 | 大陸商藥捷安康(南京)科技股份有限公司 | 磷酸二酯酶抑制劑的用途和藥盒 |
JP7326662B2 (ja) * | 2019-03-15 | 2023-08-16 | トランステラ サイエンシーズ (ナンジン), インコーポレイテッド | ホスホジエステラーゼ阻害剤の結晶形、その調製方法、及びその使用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4324893A (en) | 1979-04-18 | 1982-04-13 | American Home Products Corporation | 4-Amino-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
JPS55164682A (en) * | 1979-06-11 | 1980-12-22 | Yamanouchi Pharmaceut Co Ltd | 1-alkyl-2-oxo-2h-1,8-naphthyridine derivative and its preparation |
EP0267691A3 (en) * | 1986-10-15 | 1989-08-23 | Schering Corporation | Use of 1-substituted naphthyridine and pyridopyrazine derivatives for the preparation of medicaments with immunosuppressor activity. |
WO1994012499A1 (en) * | 1992-12-01 | 1994-06-09 | The Green Cross Corporation | 1,8-naphthyridin-2-one derivative and use thereof_ |
JPH0710875A (ja) | 1993-06-21 | 1995-01-13 | Green Cross Corp:The | 選択的ホスホジエステラーゼiv阻害剤 |
JPH07126268A (ja) * | 1993-10-29 | 1995-05-16 | Otsuka Pharmaceut Factory Inc | 1,8−ナフチリジン誘導体 |
MX9701600A (es) * | 1994-08-29 | 1997-05-31 | Yamanouchi Pharma Co Ltd | Derivados de naftiridina novedosos y composicion medicinal de los mismos. |
AU699091B2 (en) * | 1995-05-31 | 1998-11-19 | Dainippon Sumitomo Pharma Co., Ltd. | Novel naphthyridine derivatives |
NZ335766A (en) * | 1996-11-26 | 2000-11-24 | Sumitomo Pharma | Naphthyridine derivatives and use as acyl-CoA cholesterol acyl transferase(ACAT) inhibitor as treatment of hyperlipidemia |
AU2547399A (en) | 1998-02-25 | 1999-09-15 | Sumitomo Pharmaceuticals Company, Limited | Pyridone derivatives and process for producing the same |
-
2000
- 2000-10-23 AR ARP000105559A patent/AR029185A1/es active IP Right Grant
- 2000-10-23 TW TW089122260A patent/TWI262919B/zh not_active IP Right Cessation
- 2000-10-24 MX MXPA02004122A patent/MXPA02004122A/es active IP Right Grant
- 2000-10-24 US US10/111,077 patent/US6740662B1/en not_active Expired - Fee Related
- 2000-10-24 CA CA002385178A patent/CA2385178A1/en not_active Abandoned
- 2000-10-24 BR BR0014981-0A patent/BR0014981A/pt not_active Application Discontinuation
- 2000-10-24 PL PL00354600A patent/PL354600A1/xx not_active IP Right Cessation
- 2000-10-24 AT AT00970038T patent/ATE305470T1/de not_active IP Right Cessation
- 2000-10-24 AU AU79560/00A patent/AU779081B2/en not_active Ceased
- 2000-10-24 DE DE60022893T patent/DE60022893T2/de not_active Expired - Lifetime
- 2000-10-24 KR KR1020027005261A patent/KR100699395B1/ko not_active IP Right Cessation
- 2000-10-24 CN CNB008147663A patent/CN1148369C/zh not_active Expired - Fee Related
- 2000-10-24 EP EP00970038A patent/EP1225173B1/en not_active Expired - Lifetime
- 2000-10-24 RU RU2002111005/04A patent/RU2240322C2/ru not_active IP Right Cessation
- 2000-10-24 WO PCT/JP2000/007433 patent/WO2001030779A1/ja active IP Right Grant
- 2000-10-24 ES ES00970038T patent/ES2250200T3/es not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
AR029185A1 (es) | 2003-06-18 |
BR0014981A (pt) | 2002-07-16 |
EP1225173A1 (en) | 2002-07-24 |
EP1225173A4 (en) | 2003-08-20 |
US6740662B1 (en) | 2004-05-25 |
AU779081B2 (en) | 2005-01-06 |
CN1148369C (zh) | 2004-05-05 |
DE60022893D1 (de) | 2006-02-09 |
WO2001030779A1 (fr) | 2001-05-03 |
DE60022893T2 (de) | 2006-07-13 |
MXPA02004122A (es) | 2003-02-12 |
ATE305470T1 (de) | 2005-10-15 |
CN1382141A (zh) | 2002-11-27 |
KR100699395B1 (ko) | 2007-03-27 |
CA2385178A1 (en) | 2001-05-03 |
EP1225173B1 (en) | 2005-09-28 |
PL354600A1 (en) | 2004-01-26 |
RU2240322C2 (ru) | 2004-11-20 |
AU7956000A (en) | 2001-05-08 |
ES2250200T3 (es) | 2006-04-16 |
KR20020041477A (ko) | 2002-06-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI262919B (en) | Naphthyridine derivative | |
TW200461B (zh) | ||
TWI336328B (en) | Rho-kinase inhibitors | |
CN103929961A (zh) | 化合物及其治疗应用 | |
TW201908293A (zh) | 作為rock抑制劑之5員及雙環雜環醯胺 | |
CN100513407C (zh) | 三环δ阿片样物质调节剂 | |
TW200538131A (en) | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions | |
JP2004521872A (ja) | 新規なピリジン置換ピラゾロピリジン誘導体 | |
AU2002221753B2 (en) | Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same | |
FR2921926A1 (fr) | Derives de quinazolinedione,leur preparation et leurs applications therapeutiques. | |
WO2007042668A1 (fr) | Derives de la 1-amino-isoquinoline, leur preparation et leur application en therapeutique dans le traitement d' un dysfonctionnement lie au recepteur 1 de la mch | |
JP2021513530A (ja) | テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用 | |
TW201208687A (en) | Condensed ring pyridine compound | |
TW294595B (zh) | ||
WO1988007530A1 (en) | Psychotropic bicyclic imides | |
US20050222186A1 (en) | Substituted diaminopyrimidines | |
TW200904449A (en) | Dibenzo[b,f][1,4]oxazapine compounds | |
TW201030000A (en) | (Dihydro) naphthyridinone derivatives as histamine H3 receptor antagonists | |
AP424A (en) | Piperidine derivatives, their preparation and their application in therapy. | |
TWI221838B (en) | Pyrazinoisoquinoline compound or naphthalene compound | |
WO2003002532A1 (en) | Cyclic diamine compounds having fused-ring groups | |
CA2727669A1 (fr) | Nouveaux derives de (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75 | |
JP2007507464A (ja) | 新規のアミノピリジン誘導体 | |
TW215090B (zh) | ||
TW518334B (en) | Tricyclic/carboxamide compounds having anti-convulsant activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Annulment or lapse of patent due to non-payment of fees |